PLoS ONE (Jan 2021)

Role of circulating angiogenin levels in portal hypertension and TIPS.

  • Alexander Queck,
  • Frank E Uschner,
  • Philip G Ferstl,
  • Martin Schulz,
  • Maximilian J Brol,
  • Michael Praktiknjo,
  • Robert Schierwagen,
  • Sabine Klein,
  • Christian P Strassburg,
  • Carsten Meyer,
  • Christian Jansen,
  • Marie-Luise Berres,
  • Jonel Trebicka

DOI
https://doi.org/10.1371/journal.pone.0256473
Journal volume & issue
Vol. 16, no. 8
p. e0256473

Abstract

Read online

BackgroundPathogenesis of portal hypertension is multifactorial and includes pathologic intrahepatic angiogenesis, whereby TIPS insertion is an effective therapy of portal hypertension associated complications. While angiogenin is a potent contributor to angiogenesis in general, little is known about its impact on TIPS function over time.MethodsIn a total of 118 samples from 47 patients, angiogenin concentrations were measured in portal and inferior caval vein plasma at TIPS insertion (each blood compartment n = 23) or angiographic intervention after TIPS (each blood compartment n = 36) and its relationship with patient outcome was investigated.ResultsAngiogenin levels in the inferior caval vein were significantly higher compared to the portal vein (P = 0.048). Ten to 14 days after TIPS, inferior caval vein angiogenin level correlated inversely with the portal systemic pressure gradient (PConclusionIn cirrhosis patients with complications of severe portal hypertension, circulating levels of angiogenin are derived from the injured liver. Moreover, angiogenin levels in the inferior caval vein after TIPS may predict TIPS dysfunction.